- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Longeveron stellt Daten zur Alzheimer-Therapie auf der CTAD 2025 vor | 2 | Investing.com Deutsch | ||
| Mi | Longeveron to present Alzheimer's treatment data at CTAD 2025 | 1 | Investing.com | ||
| 12.11. | Longeveron secures patent for stem cell therapy targeting aging frailty | 2 | Investing.com | ||
| 12.11. | Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy | 362 | GlobeNewswire (Europe) | The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved... ► Artikel lesen | |
| 12.11. | Longeveron: Zwei Vorstandsmitglieder legen Ämter nieder | 4 | Investing.com Deutsch | ||
| 12.11. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.11. | Longeveron GAAP EPS of -$0.39 misses by $0.13, revenue of $125M beats by $124.71M | 2 | Seeking Alpha | ||
| 04.11. | Longeveron Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 03.11. | Earnings Preview For Longeveron | 2 | Benzinga.com | ||
| 27.10. | Longeveron Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect | 1 | GlobeNewswire (USA) | ||
| 01.10. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | Longeveron beruft Teamarzt der St. Louis Cardinals in den Verwaltungsrat | 3 | Investing.com Deutsch | ||
| 01.10. | George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron Board of Directors | 1 | GlobeNewswire (USA) | ||
| 22.09. | Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa | 1 | GlobeNewswire (USA) | ||
| 19.09. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.09. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.09. | Longeveron appoints interim CEO | 2 | Seeking Alpha | ||
| 03.09. | Longeveron names Than Powell as interim CEO in leadership shuffle | 2 | Investing.com | ||
| 03.09. | Longeveron Announces Key Leadership Updates | 133 | GlobeNewswire (Europe) | Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa'el... ► Artikel lesen | |
| 18.08. | Roth slashes price target on Longeveron | 4 | Cantech Letter |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,346 | -0,59 % | HV-Termine: Hauptversammlungen bei artnet, BVB, Cherry, CureVac, Schloss Wachenheim, SDM, The Grounds | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,200 | +1,38 % | Crispr Therapeutics gains amid takeover speculation | ||
| OCUGEN | 0,994 | -0,93 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| EDITAS MEDICINE | 2,119 | +1,05 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| CYTODYN | 0,280 | +12,00 % | CytoDyn Inc. - 8-K, Current Report | ||
| SOL GLOBAL INVESTMENTS | 0,012 | -10,79 % | SOL Global Investments Corp.: SOL Global Announces Change of Auditor | Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") today announce that it has changed its auditor... ► Artikel lesen | |
| TRINITY BIOTECH | 0,889 | +6,54 % | Trinity Biotech plc: Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation | DUBLIN, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,884 | -0,70 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 2,793 | -1,17 % | ANAVEX LIFE SCIENCES CORP - Jetzt droht der Kursausbruch! | ||
| ARCTURUS THERAPEUTICS | 6,240 | +5,76 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| CERUS | 1,394 | -0,57 % | Cerus stock holds Neutral rating at BTIG despite Q3 beat and raise | ||
| OVID THERAPEUTICS | 1,020 | -5,56 % | Ovid Therapeutics Inc.: Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results | Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT)... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,108 | -1,82 % | Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee | The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed... ► Artikel lesen | |
| APTEVO THERAPEUTICS | 1,130 | +4,63 % | Aptevo Therapeutics: Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors | First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting SEATTLE, WASHINGTON / ACCESS Newswire / November 10, 2025 / Aptevo Therapeutics ("Aptevo"... ► Artikel lesen | |
| HARVARD BIOSCIENCE | 0,550 | 0,00 % | Harvard Bioscience, Inc.: Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States | HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a leading provider of innovative laboratory equipment, is pleased... ► Artikel lesen |
Das Unternehmen LONGEVERON INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,003 (-0,45 %) liegt der Kurs bei 0,601 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.